Wilken F	FIS_100925
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients